Lipoprotein(a) concentrations in acute myocardial infarction patients are not indicative of levels at six month follow-up.
Efthymios ZiogosMichael A VavuranakisTarek HarbPalmer L ForanMichael J BlahaSteven R JonesShenghan LaiGary GerstenblithThorsten M LeuckerPublished in: European heart journal open (2023)
Evolocumab in Acute Coronary Syndrome Trial [EVACS I] NCT03515304, Evolocumab in Patients with Acute Myocardial Infarction [EVACS II], NCT04082442.
Keyphrases
- acute myocardial infarction
- acute coronary syndrome
- percutaneous coronary intervention
- end stage renal disease
- left ventricular
- chronic kidney disease
- newly diagnosed
- ejection fraction
- low density lipoprotein
- clinical trial
- patient reported outcomes
- prognostic factors
- peritoneal dialysis
- study protocol
- coronary artery disease
- heart failure
- phase ii